Esperion Therapeutics Inc (ESPR)vsZoetis Inc (ZTS)
ESPR
Esperion Therapeutics Inc
$3.18
0.00%
HEALTHCARE · Cap: $819.47M
ZTS
Zoetis Inc
$72.97
+0.15%
HEALTHCARE · Cap: $30.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 2177% more annual revenue ($9.53B vs $418.24M). ZTS leads profitability with a 27.7% profit margin vs -1.8%. ZTS earns a higher WallStSmart Score of 58/100 (C).
ESPR
Avoid34
out of 100
Grade: F
ZTS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ESPR.
Margin of Safety
+11.3%
Fair Value
$145.00
Current Price
$72.97
$72.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 23.2% year-over-year
Attractively priced relative to earnings
Every $100 of equity generates 83 in profit
Strong operational efficiency at 40.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -260.8% — below average capital efficiency
Trading at 9.3x book value
1.2% earnings growth
Expensive relative to growth rate
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ESPR
The strongest argument for ESPR centers on Debt/Equity, Revenue Growth. Revenue growth of 23.2% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 27.7% and operating margin at 40.7%.
Bear Case : ESPR
The primary concerns for ESPR are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.
Key Dynamics to Monitor
ESPR profiles as a growth stock while ZTS is a declining play — different risk/reward profiles.
ESPR carries more volatility with a beta of 1.06 — expect wider price swings.
ESPR is growing revenue faster at 23.2% — sustainability is the question.
ZTS generates stronger free cash flow (538M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (58/100 vs 34/100), backed by strong 27.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Esperion Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?